Suppr超能文献

安达卢西亚风湿性炎症疾病患者的新冠病毒肺炎住院率及死亡率

Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia.

作者信息

Mena-Vázquez Natalia, Manrique Arija Sara, Rojas-Giménez Marta, Raya-Álvarez Enrique, Velloso-Feijoó María Luisa, López-Medina C, Ramos-Giraldez Consuelo, Godoy-Navarrete Francisco Javier, Redondo-Rodríguez Rocío, Cabezas-Lucena Alba María, Morales-Águila M, Romero-Barco C M, Fernández-Nebro Antonio

机构信息

Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.

Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.

出版信息

Reumatol Clin (Engl Ed). 2021 Mar 20;18(7):422-8. doi: 10.1016/j.reuma.2021.02.009.

Abstract

OBJECTIVE

To describe whether rheumatic inflammatory diseases (RID) are associated with a higher risk of hospitalization and/or mortality from COVID-19 and identify the factors associated with hospitalization and mortality in RID and COVID-19 in different Hospitals in Andalusia.

METHODS

Design: Multicentre observational case-control study.

PATIENTS

RID and COVID-19 from different centres in Andalusia.

CONTROLS

patients without RIS matched by sex, age and CRP-COVID. Protocol A list of patients with PCR for COVID-19 was requested from the microbiology service from March 14 to April 14, 2020. The patients who had RID were identified and then consecutively a paired control for each case. Variables The main outcome variable was hospital admission and mortality from COVID-19. Statistical analysis Bivariate followed by binary logistic regression models (DV: mortality/hospital admission).

RESULTS

One hundred and fifty-six patients were included, 78 with RID and COVID-19 and 78 without RID with COVID-19. The patients did not present characteristics of COVID-19 disease different from the general population, nor did they present higher hospital admission or mortality. The factor associated with mortality in patients with RID was advanced age (OR [95% CI], 1.1 [1.0-1.2]; p = 0.025), while the factors associated with hospitalization were advanced age (OR [95% CI], 1.1 [1.0-1.1]; p = 0.007) and hypertension (OR [95% CI], 3.9 [1.5-6.7]; p = 0.003).

CONCLUSION

Mortality and hospital admission due to COVID-19 do not seem to increase in RID. Advanced age was associated with mortality in RID and, in addition, HTN was associated with hospital admission.

摘要

目的

描述风湿性炎症性疾病(RID)是否与COVID-19导致的更高住院风险和/或死亡率相关,并确定安达卢西亚不同医院中RID合并COVID-19患者住院和死亡的相关因素。

方法

设计:多中心观察性病例对照研究。

患者

来自安达卢西亚不同中心的RID合并COVID-19患者。

对照

按性别、年龄和COVID-19相关C反应蛋白匹配的无RID患者。方案:向微生物学服务部门索要2020年3月14日至4月14日期间进行COVID-19聚合酶链反应检测的患者名单。确定患有RID的患者,然后为每个病例连续选取一名配对对照。变量:主要结局变量是COVID-19导致的住院和死亡。统计分析:双变量分析,随后进行二元逻辑回归模型(因变量:死亡率/住院率)。

结果

纳入156例患者,78例为RID合并COVID-19患者,78例为无RID的COVID-19患者。这些患者未表现出与普通人群不同的COVID-19疾病特征,也未表现出更高的住院率或死亡率。RID患者死亡的相关因素是高龄(比值比[95%置信区间],1.1[1.0 - 1.2];p = 0.025),而与住院相关的因素是高龄(比值比[95%置信区间],1.1[1.0 - 1.1];p = 0.007)和高血压(比值比[95%置信区间],3.9[1.5 - 6.7];p = 0.003)。

结论

RID患者因COVID-19导致的死亡率和住院率似乎并未增加。高龄与RID患者的死亡率相关,此外,高血压与住院率相关。

相似文献

1
Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia.
Reumatol Clin (Engl Ed). 2021 Mar 20;18(7):422-8. doi: 10.1016/j.reuma.2021.02.009.
2
Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia.
Reumatol Clin (Engl Ed). 2022 Aug-Sep;18(7):422-428. doi: 10.1016/j.reumae.2021.02.006. Epub 2021 Sep 9.
4
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
Ann Rheum Dis. 2020 Nov;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984. Epub 2020 Aug 7.
7
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
9
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001439.

引用本文的文献

1
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
Front Med (Lausanne). 2023 Mar 22;10:1152587. doi: 10.3389/fmed.2023.1152587. eCollection 2023.

本文引用的文献

1
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
Mol Cell Biochem. 2021 Feb;476(2):553-574. doi: 10.1007/s11010-020-03924-2. Epub 2020 Oct 7.
2
Risk factors for hospital admission among COVID-19 patients with diabetes. A study from Saudi Arabia.
Saudi Med J. 2020 Oct;41(10):1090-1097. doi: 10.15537/smj.2020.10.25419.
3
Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases.
Int J Clin Pract. 2021 Apr;75(4):e13707. doi: 10.1111/ijcp.13707. Epub 2020 Dec 14.
5
Clinical and CT features of the COVID-19 infection: comparison among four different age groups.
Eur Geriatr Med. 2020 Oct;11(5):843-850. doi: 10.1007/s41999-020-00356-5. Epub 2020 Jul 13.
7
Incidence and case fatality rate of COVID-19 in patients with active epilepsy.
Neurology. 2020 Sep 8;95(10):e1417-e1425. doi: 10.1212/WNL.0000000000010033. Epub 2020 Jun 17.
8
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Ann Rheum Dis. 2020 Sep;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763. Epub 2020 Jun 12.
10
Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review.
Ann Intern Med. 2020 Sep 1;173(5):362-367. doi: 10.7326/M20-3012. Epub 2020 Jun 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验